Vimarsana
Biggest News Aggregation in the World

Enrollment Expected News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Enrollment Expected. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Enrollment Expected Today - Breaking & Trending Today

EpicQuest Education Announces Agreement between Davis College and Chongqing Technology and Business Institute for Intake of At Least 46 Students in September 2023 - Vimarsana News

EpicQuest Education Announces Agreement between Davis College and Chongqing Technology and Business Institute for Intake of At Least 46 Students in September 2023

/PRNewswire/ -- EpicQuest Education Group International Limited (NASDAQ: EEIQ), ("EpicQuest Education", "EEIQ" or the "Company"), a provider of comprehensive...

Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update - Vimarsana News

Viking Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

/PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...

uniQure Inc.: uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease - Vimarsana News

uniQure Inc.: uniQure Announces Latest Positive Recommendation from Data Safety Monitoring Board in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

~ No Significant Safety Concerns Observed in First Four Patients Enrolled in Higher-dose Cohort ~ ~ Enrollment Expected to be Completed by Mid-2022 ~ LEXINGTON, Mass. and AMSTERDAM, Nov. 02, 2021.